1. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
- Author
-
Grasso F, Negri DR, Mochi S, Rossi A, Cesolini A, Giovannelli A, Chiantore MV, Leone P, Giorgi C, and Cara A
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes virology, Calreticulin biosynthesis, Calreticulin genetics, Calreticulin immunology, Cancer Vaccines therapeutic use, Cell Line, Tumor, Female, Gene Expression, Genetic Vectors, Humans, Immunity, Cellular, Immunity, Humoral, Interferon-gamma metabolism, Kaplan-Meier Estimate, Lentivirus enzymology, Mice, Mice, Inbred C57BL, Papillomavirus E7 Proteins biosynthesis, Papillomavirus E7 Proteins immunology, Papillomavirus Infections immunology, Papillomavirus Infections pathology, Papillomavirus Infections virology, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Tumor Burden, Uterine Cervical Neoplasms immunology, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms virology, Vaccination, Xenograft Model Antitumor Assays, Cancer Vaccines administration & dosage, Integrases genetics, Lentivirus genetics, Papillomavirus E7 Proteins genetics, Papillomavirus Infections prevention & control, Uterine Cervical Neoplasms prevention & control
- Abstract
Persistent infection with high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer, one of most common cancer among woman worldwide, and represents an important risk factor associated with other anogenital and oropharyngeal cancers in men and women. Here, we designed a therapeutic vaccine based on integrase defective lentiviral vector (IDLV) to deliver a mutated nononcogenic form of HPV16 E7 protein, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer, fused to calreticulin (CRT), a protein able to enhance major histocompatibility complex class I antigen presentation (IDLV-CRT/E7). Vaccination with IDLV-CRT/E7 induced a potent and persistent E7-specific T cell response up to 1 year after a single immunization. Importantly, a single immunization with IDLV-CRT/E7 was able to prevent growth of E7-expressing TC-1 tumor cells and to eradicate established tumors in mice. The strong therapeutic effect induced by the IDLV-based vaccine in this preclinical model suggests that this strategy may be further exploited as a safe and attractive anticancer immunotherapeutic vaccine in humans., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF